Assessment of quality of life of type 2 diabetes patients with newly diagnosed non alcoholic fatty liver disease using quality of life instrument for Indian diabetes patients

Abstract

Introduction: Non alcoholic fatty liver disease is emerging as a public health problem among type 2 diabetes mellitus patients. It has an impact on quality of life, which is meagrely explored. Aim: To assess quality of life of type 2 diabetes patients with newly diagnosed non alcoholic fatty liver disease. Materials and Methods: Confirmed cases of newly diagnosed non alcoholic fatty liver disease with type 2 diabetes mellitus (n = 55) were enrolled. Clinical, anthropometric and medical profiles were assessed. Quality of life was assessed with the help of quality of life instrument for Indian diabetes patients. Results: Weight (P = 0.005) and body mass index (P 0.008) in grade 3 hepatic steatosis were higher than grade 2 steatosis. Physical health deteriorated from grade 1 to grade 3 hepatic steatosis. The mean likert scores decreased significantly (P 0.000) from grade 2 to grade 3 and between grade 1 and grade 3 (P 0.0014) hepatic steatosis in the physical endurance domain. Perceptions regarding general health and treatment satisfaction revealed existing loopholes in the health system and one′s general attitude towards health. The dietary domain was marked with gross dissatisfaction amongst most with hepatic steatosis with a significant reduction in mean likert scale score between grade 1 and grade 2 (P 0.012) of hepatic steatosis. Conclusions: Modifiable domains of quality of life should be addressed as a core component of standard care in newly diagnosed non alcoholic fatty liver disease with type 2 diabetes mellitus to avert future cardiac and hepatic events.

Body mass index - nonalcoholic fatty liver disease - quality of life instrument for Indian diabetes patients - quality of life - type 2 diabetes mellitus

• References

• 1 Lizardi-Cervera J, Aguilar-Zapata D. Nonalcoholic fatty liver disease and its association with cardiovascular disease. Ann Hepatol 2009; 8: S40-S43
• 2 LaBrecque D, Abbas Z, Anania F, Ferenci P, Khan AG, Goh KL. et al. Non alcoholic fatty liver disease and nonalcoholic steatohepatitis. WGO Global Guidelines; 2012: 1-29 Available at http://www.worldgastroenterology.org/assets/export/userfiles/2012_NASH%20and%20NAFLD_Final_long.pdf
• 3 Medina J, Fernandez-Salazar LI, Garcia-Buey L, Moreno-Otero R. Approach to the pathogenesis and treatment of non-alcoholic steatohepatitis. Diabetes Care 2004; 27: 2057-2066
• 4 Skevington SM, Lotfy M, O′Connell KA. The World Health Organisation′s WHOQOL-BREF quality of life assessment: Psychometric properties and results of the international field trial. A report from the WHO QOL Group. Qual Life Res 2004; 13: 299-310
• 5 David K, Kowdley KV, Unalp A, Kanwal F, Brunt EM, Schwimmer JB. et al. Quality of Life in Adults with Nonalcoholic Fatty Liver Disease: Baseline Data from the Nonalcoholic Steatohepatitis Clinical Research Network. Hepatology 2009; 49: 1904-1912
• 6 Younossi ZM, Boparai N, Price LL, Kiwi ML, McCormick M, Guyatt G. Health-related quality of life in chronic liver disease: the impact of type and severity of disease. Am J Gastroenterol 2001; 96: 2199-2205
• 7 Younossi ZM, Boparai N, McCormick M, Price LL, Guyatt G. Assessment of utilities and health-related quality of life in patients with chronic liver disease. Am J Gastroenterol 2001; 96: 579-583
• 8 Dan AA, Kallman JB, Wheeler A, Younoszai Z, Collantes R, Bondini S. et al. Health-related quality of life in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2007; 26: 815-820
• 9 Nagpal J, Kumar A, Kakar S, Bhartia A. The Development of ′Quality of Life Instrument for Indian Diabetes Patients (QOLID): A Validation and Reliability Study in Middle and Higher Income Groups. J Assoc Physicians India 2010; 58: 295-304
• 10 Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-2474
• 11 Rubin RR, Peyrot M. Quality of Life and Diabetes. Diabetes Metab Res Rev 1999; 15: 205-218
• 12 Baumeister SE, Volzke H, Marschall P, John U, Schmidt CO, Flessa S. et al. Impact of fatty liver disease on health care utilization and costs in a general population: A 5-year observation. Gastroenterology 2008; 134: 85-94
• 13 Testa MA, Simonson DC. Assessment of quality of life outcomes. N Engl J Med 1996; 334: 835-840
• 14 Thier SO. Forces motivating the use of health status assessment measures in clinical settings and related clinical research. Med Care 1992; 30 (Suppl) MS15-MS22
• 15 Kempf K, Martin S. Autonomous exercise game use improves metabolic control and quality of life in type 2 diabetes patients - a randomized controlled trial. BMC Endocr Disord 2013; 13: 57
• 16 Myers VH, Mcvay MA, Brashear MM, Johannsen NM, Swift DL, Kramer K. et al. Exercise Training and Quality of Life in Individuals With Type 2 Diabetes A randomized controlled trial. Diabetes Care 2013; 36: 1884-1890
• 17 Krass I, Dhippayom T. Pharmaceutical care - impact on quality of life in patients with type 2 diabetes: A review. Clin Audit 2013; 5: 17-32